Drug intelligence / Profile preview

C2406

Development stage: Phase 1
Modality: Small Molecules
Administration: Oral (inferred From The Context Of The Trial Design; Not Explicitly Confirmed)

Overview

C2406 is an investigational drug currently being studied in clinical trials, including a pharmacokinetic, pharmacodynamic, and drug-drug interaction study with Epaminurad in healthy subjects. Specific details about its mechanism of action, chemical structure, or therapeutic indication have not been disclosed in public sources as of June 2025. The available information only confirms its status as a distinct experimental compound under evaluation for potential pharmaceutical use[1].

Other names: C2406C-2406C 2406

Beyond the preview

Go deeper on C2406.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on C2406.

Explore the full profile